share_log

賽生藥業：根據《收購守則》規則22作出的交易披露

SCICLONE PHARMA: Disclosure of Dealings under Rule 22 of the Takeovers Code

Hong Kong Stock Exchange ·  Apr 30 06:13
Summary by Moomoo AI
赛生药业（SCICLONE PHARMA）於2024年4月30日宣布，公司執行人員林惠斌根據香港《公司收購及合併守則》規則22，於2024年4月29日透過協議安排進行了股份交易。林惠斌在首次公開發售後受限股份單位計劃下獲得10,000股股份獎勵，並以每股0.0000港元的價格買入該批股份，交易後持股數量增至29,967股，佔公司已發行股份的0.0048%。
赛生药业（SCICLONE PHARMA）於2024年4月30日宣布，公司執行人員林惠斌根據香港《公司收購及合併守則》規則22，於2024年4月29日透過協議安排進行了股份交易。林惠斌在首次公開發售後受限股份單位計劃下獲得10,000股股份獎勵，並以每股0.0000港元的價格買入該批股份，交易後持股數量增至29,967股，佔公司已發行股份的0.0048%。
SCICLONE PHARMA (SCICLONE PHARMA) ANNOUNCED ON 30 APRIL 2024 THAT ITS EXECUTIVE OFFICER LIN HUI-BIN HAD ENTERED INTO A SHARE TRANSACTION BY AGREEMENT ON 29 APRIL 2024 PURSUANT TO RULE 22 OF THE HONG KONG CODE OF BUSINESS ACQUISITIONS AND MERGERS. Lin Huibin received a 10,000 share bonus under the Initial Public Offering Limited Share Unit Scheme and purchased the lot at HK$0.0000 per share. The number of holdings after the transaction increased to 29,967 shares, representing 0.0048% of the issued shares of the company.
SCICLONE PHARMA (SCICLONE PHARMA) ANNOUNCED ON 30 APRIL 2024 THAT ITS EXECUTIVE OFFICER LIN HUI-BIN HAD ENTERED INTO A SHARE TRANSACTION BY AGREEMENT ON 29 APRIL 2024 PURSUANT TO RULE 22 OF THE HONG KONG CODE OF BUSINESS ACQUISITIONS AND MERGERS. Lin Huibin received a 10,000 share bonus under the Initial Public Offering Limited Share Unit Scheme and purchased the lot at HK$0.0000 per share. The number of holdings after the transaction increased to 29,967 shares, representing 0.0048% of the issued shares of the company.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more